Skip to Content

Methylergonovine Pregnancy and Breastfeeding Warnings

Methylergonovine is also known as: Methergine

Medically reviewed on October 9, 2017

Methylergonovine Pregnancy Warnings

Methylergonovine has been assigned to pregnancy category C by the FDA. Animal reproductive studies have not been reported. There are no controlled data in human pregnancy. Use of methylergonovine is contraindicated during pregnancy because of its uterotonic effects.

See references

Methylergonovine Breastfeeding Warnings

Methylergonovine may be administered orally for a maximum of 1 week postpartum to control uterine bleeding. Recommended dosage is 0.2 mg orally 3 or 4 times daily. At this dosage level a small quantity of drug appears in human milk. Mothers should not breast-feed during treatment with methylergonovine and for at least 12 hours after administration of the last dose. Milk secreted during this period should be discarded.

See references

References for pregnancy information

  1. "Product Information. Methergine (methylergonovine)." Allscripts Healthcare Solutions, Chicago, IL.

References for breastfeeding information

  1. "Product Information. Methergine (methylergonovine)." Allscripts Healthcare Solutions, Chicago, IL.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide